<DOC>
	<DOCNO>NCT01963325</DOCNO>
	<brief_summary>This phase II study design evaluate efficacy safety S-1 plus Abraxane second-line treatment cholangiocarcinoma .</brief_summary>
	<brief_title>S-1 Combination With Abraxane Treating Cholangiocarcinoma</brief_title>
	<detailed_description>There standard second-line treatment cholangiocarcinoma , new therapy need . The efficacy S-1 first-line treatment cholangiocarcinoma confirm several study . The IMPACT study show Abraxane plus gemcitabine provide well survival gemcitabine alone . Since cholangiocarcinoma display similar sensitivity chemotherapy use pancreatic carcinoma , assume S-1 plus Abraxane effective safe treat cholangiocarcinoma .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologic cytologic diagnosis cholangiocarcinoma Not eligible curative surgery Progressed firstline gemcitabinebased chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status 2 good No serious uncontrolled concomitant medical illness Adequate bone marrow function ( absolute neutrophil count ≧1,500 ul , platelet count ≧90,000/ul ) , hemoglobin : &gt; equal 8 mg/dL , total bilirubin : &lt; equal 1.5 X institutional upper limit normal , calculated creatinine clearance great equal 60 mL/min ( calculate Cockcroft Gault method ) . Uncontrolled infection severe active comorbid disease Previous malignancy past five year , exclude nonmelanoma skin cancer situ cervical , bladder uterine cancer Pregnancy lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>